Clinical Trials Directory

Trials / Completed

CompletedNCT00447629

Study Evaluating Single Doses of PPM-204 on the Electrical Pathways of the Heart

A Randomized, Double-Blind, Placebo- and Moxifloxacin (Open-Label)- Controlled, 4-Period Crossover Study of the Effects of Single Oral Doses of PPM 204 on Cardiac Repolarization in Healthy Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer · Industry
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

A study evaluating the safety of a high and low dose of PPM-204 on the electrical pathways of the heart.

Conditions

Interventions

TypeNameDescription
DRUGPPM-204

Timeline

Start date
2007-01-01
Completion
2007-03-01
First posted
2007-03-15
Last updated
2007-12-05

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00447629. Inclusion in this directory is not an endorsement.

Study Evaluating Single Doses of PPM-204 on the Electrical Pathways of the Heart (NCT00447629) · Clinical Trials Directory